# CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

> **NCT07335497** · PHASE1,PHASE2 · RECRUITING · sponsor: **Crescent Biopharma, Inc.** · enrollment: 290 (estimated)

## Conditions studied

- Locally Advanced / Metastatic Solid Tumors

## Interventions

- **DRUG:** CR-001

## Key facts

- **NCT ID:** NCT07335497
- **Lead sponsor:** Crescent Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-17
- **Primary completion:** 2029-02
- **Final completion:** 2029-02
- **Target enrollment:** 290 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07335497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07335497, "CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07335497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*